atractylenolide i

1. Atractylenolide-I has an anti-inflammatory effect by inhibiting TNF-α and IL-6 production; ameliorates sepsis syndrome, liver and kidney functions by reduction of pro-inflammatory cytokines and LPS. 2. Atractylenolide-I significantly sensitizes the res

Atractylenolide I (Standard) is a reference standard for research and analysis in studies involving Atractylenolide I. 1. Atractylenolide-I has an anti-inflammatory effect by inhibiting TNF-α and IL-6 production; ameliorates sepsis syndrome, liver and kidney functions by reduction of pro-inflammatory cytokines and LPS. 2. Atractylenolide-I significantly sensitizes the response of MyD88(+) EOC cells to paclitaxel by blocking MD-2-mediated TLR4/MyD88 signaling.

Atractylenolide IV is a useful organic compound for research related to life sciences. The catalog number is T125815 and the CAS number is 147396-00-7.

Atractylenolide III (ICodonolactone) may have therapeutic potential in treating homocysteine-mediated cognitive impairment and neuronal injury. Atractylenolide III is a potential candidate for the treatment of human lung carcinoma by inducing the release of cytochrome c, upregulating the expression of Bax and translocating apoptosis-inducing factor.

1. Atractylenolide II (2-Atractylenolide) has antimelanoma effect by inhibiting STAT3 signalling. 2. Atractylenolide II has cytotoxic/apoptotic effects may via p38 activation , ERK and Akt inactivation, p53 dependent.

Atractylenolide II (Standard) is a reference standard for research and analysis in studies involving Atractylenolide II. 1. Atractylenolide II (2-Atractylenolide) has antimelanoma effect by inhibiting STAT3 signalling. 2. Atractylenolide II has cytotoxic/apoptotic effects may via p38 activation , ERK and Akt inactivation, p53 dependent.

Atractylenolide III (Standard) is a reference standard for research and analysis in studies involving Atractylenolide III. Atractylenolide III (ICodonolactone) may have therapeutic potential in treating homocysteine-mediated cognitive impairment and neuronal injury. Atractylenolide III is a potential candidate for the treatment of human lung carcinoma by inducing the release of cytochrome c, upregulating the expression of Bax and translocating apoptosis-inducing factor.

8beta-Methoxyatractylenolide I is a natural product from Atractylodes macrocephala.